Eli Lilly and Co

NYSE:LLYUnited States

Today

Show headlines and story abstract

• DJ Eli Lilly to Buy Morphic Holding for $3.2 Billion -- Update, from 23 minutes ago by Dow Jones

  23 minutes ago by Dow Jones
  Companies Mentioned: LLY, MORF
  
  By Colin Kellaher
  
  Eli Lilly has agreed to buy biopharmaceutical company Morphic Holding for $3.2 billion in a deal that bolsters the drugmaker's immunology pipeline.
  

• DJ Morphic's Stock Rockets After $3.2 Billion Buyout Deal With Eli Lilly -- MarketWatch, from 27 minutes ago by Dow Jones

  27 minutes ago by Dow Jones
  Companies Mentioned: LLY, MORF
  
  Shares of Morphic Holding Inc. (MORF) rocketed 76% in premarket trading Monday, after the biopharmaceutical company announced an agreement to be acquired by Eli Lilly & Co. (LLY) in a cash deal valued at about $3.2 billion. Lilly's stock (LLY) tacked on 0.2% ahead of the open. Under terms of the deal, Lilly will pay $57 for each Morphic share outstanding, which is 79% above Friday's closing price of $31.84. "Oral therapies could open up new possibilities for earlier intervention in diseases like ulcerative colitis, and also provide the potential for combination therapy to help patients with more severe disease," said Daniel Skovronsky, chief scientific officer at Lilly Research Laboratories. Morphic's lead program is a treatment for inflammatory bowel disease, that is currently being evaluated in Phase 2 studies in ulcerative colitis and in Crohn's disease. Morphic's stock had gained 10.3% year to date through Friday, while Lilly shares have soared 56.9% and the S&P 500 has advanced 16.7%.
  

• DJ Eli Lilly to Buy Morphic Holding for $3.2 Billion, from 33 minutes ago by Dow Jones

  33 minutes ago by Dow Jones
  Companies Mentioned: LLY, MORF
  
  By Colin Kellaher
  
  Eli Lilly has agreed to buy biopharmaceutical company Morphic Holding for $3.2 billion in a deal that bolsters the drugmaker's immunology pipeline.
  

• *DJ Lilly To Acquire Morphic To Improve Outcomes For Patients With Inflammatory Bowel Disease >LLY MORF, from 38 minutes ago by Dow Jones

  38 minutes ago by Dow Jones
  Companies Mentioned: LLY, MORF

• Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease, from 38 minutes ago by Dow Jones

  38 minutes ago by Dow Jones
  Companies Mentioned: LLY, MORF
  
  The tender offer for all of the outstanding shares of Morphic described in this communication has not yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any securities, nor is it a substitute for the tender offer materials that Lilly and its acquisition subsidiary will file with the SEC upon commencement of the tender offer. A solicitation and offer to buy outstanding shares of Morphic will only be made pursuant to the tender offer materials that Lilly and its acquisition subsidiary intend to file with the SEC. At the time the tender offer is commenced, Lilly and its acquisition subsidiary will file tender offer materials on Schedule TO, and Morphic will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED ACQUISITION AND THE PARTIES THERETO. INVESTORS AND STOCKHOLDERS OF MORPHIC ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE (AND EACH AS IT MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT INVESTORS AND STOCKHOLDERS OF MORPHIC SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES OF COMMON STOCK IN THE TENDER OFFER. The tender offer materials (including the Offer to Purchase and the related Letter of Transmittal), as well as the Solicitation/Recommendation Statement, will be made available to all investors and stockholders of Morphic at no expense to them at Lilly's website at investor.lilly.com and (once they become available) will be mailed to the stockholders of Morphic free of charge. Copies of the documents filed with the SEC by Morphic will be available free of charge on Morphic's website, investor.morphictx.com, or by contacting Morphic's investor relations department at chris.erdman@morphictx.com. The information contained in, or that can be accessed through, Morphic's and Lilly's websites is not a part of, or incorporated by reference herein. The tender offer materials (including the Offer to Purchase and the related Letter of Transmittal), as well as the Solicitation/Recommendation Statement, will also be made available for free on the SEC's website at www.sec.gov. In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Lilly and Morphic file annual, quarterly, and current reports, proxy statements and other information with the SEC. You may read any reports, statements or other information filed by Lilly and Morphic with the SEC for free on the SEC's website at www.sec.gov.